Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Validation and Performance SERO Comparison of Three SARS-CoV-2 Antibody SERO Assays

    Authors: Shaolei Lu; Kimberly J Paiva; Ricky D Grisson; Philip A Chan; John Lonks; Ewa King; Richard C Huard; Diane L Pytel-Parenteau; Ga Hie Nam; Evgeny Yakirevich

    doi:10.1101/2020.05.29.124776 Date: 2020-05-30 Source: bioRxiv

    Serology testing of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is increasingly being used during the current pandemic of Coronavirus Disease MESHD 2019 (COVID-19). The clinical and epidemiologic utilities of antibody SERO-based SARS-CoV-2 testing are under debate. Characterizing these assays helps to understand the disease and provides scientific basis for deciding how to best use these assays. The study assessed one chemiluminescent assay (Abbott COVID-2 IgG) and two lateral flow assays (STANDARD Q [SQ] IgM/IgG Duo and Wondfo Total Antibody Test SERO). Validation included 113 blood SERO samples from 71 PCR-confirmed COVID-19 patients and 1182 samples from negative controls with potential interferences/cross-reactions, including 1063 pre-pandemic samples. IgM antibodies SERO against SARS-CoV-2 were detected as early as post- symptom onset TRANS days 3-4. IgG antibodies SERO were first detected post-onset days 5-6 by SQ assays. The detection rates increased gradually, and SQ IgG, Abbott IgG and Wondfo Total detected antibodies SERO from all the PCR-confirmed patients 14 days after symptom onset TRANS. Overall agreements between SQ IgM/IgG and Wondfo Total was 88.5% and between SQ IgG and Abbott IgG was 94.6% (Kappa = 0.75, 0.89). No cross-reaction with other endemic coronavirus infections MESHD were identified. Viral hepatitis HP Viral hepatitis MESHD and autoimmune samples were the main cross-reactions observed. However, the interferences/cross-reactions were low. The specificities were 100% for SQ IgG and Wondfo Total and 99.62% for Abbott IgG and 98.87% for SQ IgM. These findings demonstrate high sensitivity SERO and specificity of appropriately validated antibody SERO-based SARS-CoV-2 assays with implications for clinical use and epidemiological seroprevalence SERO studies.View Full Text

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.